5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer

M. Lopez, M. Natali, L. Di Lauro, G. Tonini, S. Carpano, P. Vici, E. M S Conti

Research output: Contribution to journalArticle

Abstract

Forty-eight patients with advanced measurable gastric cancer were treated with the three-drug combination of 5-fluorouracil, epirubicin, and BCNU (FEB). The response rate was 42% in 45 evaluable patients. There were five complete responders (11%). The median duration of response was 13 months, and the median survival of all patients was 9.2 months. Toxicity was generally mild to moderate. No instances of congestive heart failure were recorded. These results indicate that patients with metastatic gastric cancer can be effectively palliated with FEB chemotherapy.

Original languageEnglish
Pages (from-to)204-207
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number3
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of '5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer'. Together they form a unique fingerprint.

  • Cite this

    Lopez, M., Natali, M., Di Lauro, L., Tonini, G., Carpano, S., Vici, P., & Conti, E. M. S. (1990). 5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 13(3), 204-207.